Roivant Sciences Ltd ROIV.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of ten analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -34 cents to -11 cents per share.
Revenue fell 87.9% to $4.48 million from a year ago; analysts expected $49.22 million.
Roivant Sciences Ltd's reported EPS for the quarter was a loss of 31 cents.
The company reported a quarterly loss of $230.18 million.
Roivant Sciences Ltd shares had risen by 2.3% this quarter and gained 5.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 9.6% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Roivant Sciences Ltd is $17.00
This summary was machine generated from LSEG data November 12 at 01:38 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.26 | -0.31 | Missed |
Jun. 30 2024 | -0.32 | 0.12 | Beat |
Mar. 31 2024 | -0.30 | -0.19 | Beat |
Dec. 31 2023 | -0.32 | -0.30 | Beat |
Comments